Principal Investigators

    Mathias S. Toft

    Institution

    University Hospital Oslo

    Contact information of lead PI

    Country

    Norway

    Title of project or programme

    Parkinson's disease - from genetic risk factors to molecular mechanisms and clinical phenotypes

    Source of funding information

    RCN

    Total sum awarded (Euro)

    € 728,408

    Start date of award

    01/01/2016

    Total duration of award in years

    3.0

    The project/programme is most relevant to:

    Parkinson's disease & PD-related disorders

    Keywords

    Research Abstract

    This project is a cutting-edge study of Parkinson disease (PD), a devastating disease of the central nervous system affecting at least 5,000 adults in Norway. Over the last decade, research has demonstrated that vulnerability to brain disorders has a profound genetic component. A major current challenge is to identify the relevant molecular mechanisms and characterize how variability on the level of genes and pathways translates into the phenotypically diverse condition seen in clinical practice. This knowledge is crucial for the development of novel therapies targeting specific pathogenic processes, and enabling tailored treatment for the individual patient. PD is characterized by progressive decline in motor function leading to disability and impaired quality of life. Heterogeneity in clinical presentation is widely acknowledged and the rate of disease progression varies considerably. Through recent work our group has gained considerable insights into the genetic risk factors predisposing to PD. Building upon our experience and results from previous and ongoing research, this project is aiming to identify molecular mechanisms for disease risk and for diverse PD phenotypes. We will apply new technologies and analytical methods to disentangle genomic risk regions for PD. We will then study epigenetic mechanisms, which hold great promise to reveal new insights into pathogenesis not identified by other research areas. By combining these molecular studies with the establishment of a longitudinal cohort study, we hypothesize that we will identify mechanisms that can be targeted in improved treatment strategies.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: Norway
Diseases: Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF